Clinical Trial Update: Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients [Phase 2]

View source ↗

Summary

Phase 2 dose-range finding study completed for QBW251 in COPD patients, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QBW251

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2023-04-28